|
Session 124
Poster Abstracts
Morbidity and Mortality: Non-AIDS Events
Monday, 1-2:30 pm
Poster Hall |
| 706 |
Factors Associated with Mortality in the Study of Fat Redistribution and Metabolic Change in HIV Infection
L Modrich1,2, R Scherzer1,2, A Zolopa3, D Rimland4, C Lewis5, R Kronmal6, P Bacchetti1, C Grunfeld1,2, M Shlipak1,2, Phyllis Tien*1,2, and the FRAM Study
1Univ of California, San Francisco, US; 2VAMC, San Francisco, CA, US; 3Stanford Univ, CA, US; 4VAMC, Atlanta, GA, US; 5Univ of Alabama at Birmingham, US; and 6Univ of Washington, Seattle, US |
707
 |
Serious Fatal and Non-fatal Non-AIDS-defining Illnesses in Europe
Amanda Mocroft*1, P Reiss2, J Gasiorowski3, B Ledergerber4, A Chiesi5, J Gatell6, A Rakhmanova7, M Johnson8, O Kirk9, J Lundgren9,10, and the EuroSIDA Study Group
1Royal Free and Univ Coll Med Sch, London, UK; 2Academisch Medisch Centrum bij de Universiteit van Amsterdam, Amsterdam, The Netherlands; 3Med Univ, Wroclaw, Poland; 4Univ Hosp, Zurich, Switzerland; 5Inst Superiore di Sanita, Rome, Italy; 6Hosp Clin i Provincial, Barcelona, Spain; 7Medical Academy Botkin Hospital, St Petersburg, Russia; 8Royal Free Hosp, London, UK; 9Copenhagen HIV Program, Panum Institute, Copenhagen, Denmark; and 10Centre for Viral Disease KMA, Rigshospitalet, Copenhagen, Denmark |
| 708 |
Causes of Death in Patients Treated with ART, 1996 to 2006: Collaborative Analysis of 13 Cohort Studies
John Gill*1, M May2, C Lewden3, M Saag4, M Mugavero4, M Egger5, P Reiss6, B Ledergerber7, A Mocroft8, J Sterne2, and ART Cohort Collaboration
1Univ of Calgary, Canada; 2Univ of Bristol, UK; 3Univ Victor Segalen, Bordeaux, France; 4Univ of Alabama at Birmingham, US; 5Univ of Bern, Switzerland; 6Univ of Amsterdam, The Netherlands; 7Univ Hosp Zurich, Switzerland; and 8Royal Free and Univ Coll Med Sch, London, UK |
| 709 |
Different Rates of Discontinuation because of Toxicities According to CD4 Counts and Prior ART in Patients Starting Nevirapine-based cART: Nevirapine Toxicity Multi-cohort Collaboration
Anouk Kesselring*1, F Wit2, C Sabin3, J Lundgren4, J Gill5, J Gatell6, A Rauch7, J Montaner8, P Reiss2, and A Mocroft3
1HIV Monitoring Fndn, Amsterdam, The Netherlands; 2Academic Med Ctr, Univ of Amsterdam, The Netherlands; 3Royal Free and Univ Coll Med Sch, London, UK; 4Rigshospitalet and University of Copenhagen, Copenhagen HIV Programme, Copenhagen, Denmark; 5Univ of Calgary, Canada; 6Hosp Clin-IDIBAPS, Univ of Barcelona, Spain; 7University Hospital Bern and University of Bern, Bern, Switzerland; and 8British Columbia Center for Excellence in HIV/AIDS, St. Paul`s Hospital, Vancouver, Canada |
710
|
Updated Surveillance of Cardiovascular Event Rates among HIV-infected and HIV-uninfected Californians, 1996 to 2008
L Hurley1, W Leyden1, L Xu2, M Silverberg1, C Chao2, B Tang2, W Towner3, M Horberg1, and Daniel Klein*4
1Kaiser Permanente, Oakland, CA, US; 2Kaiser Permanente, Pasadena, CA, US; 3Kaiser Permanente, Los Angeles, CA, US; and 4Kaiser Permanente, Hayward, CA, US |
| 711 |
Reasons for Hospitalization that Occurs after HAART Initiation
Stephen Berry*, Y Manabe, R Moore, and K Gebo
Johns Hopkins Univ Sch of Med, Baltimore, MD, US |
|
